Table 2

Summary of TP53 abnormalities identified in CLL patients and their association with biologic and clinical variables

AbnormalityMonoallelic alterationsBiallelic alterations
Total2347
Type of defect (n)del(17p) (3), mutation (20)del(17p)/mutation (42), mutation/mutation (5)
Proportion of missense mutations, %10067*
High risk: Rai stage III/IV (at the time of TP53 status examination), % (n)48 (10/21)67 (29/43)
P.13< .001
Unmutated IgVH, % (n)86 (18/21)93 (41/44)
P.025.001
11q deletion, % (n)43 (10/23)11 (5/47)
P.014.055
  • P = .003 (biallelic vs monoallelic alterations in relation to 11q deletion).

  • CLL indicates chronic lymphocytic leukemia.

  • * In the subgroup del(17p)/mutation.